Company news

Arcturus Therapeutics Holdings Inc. news in 2020

Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2020, newest first.

View company

Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

December 29, 2020

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

December 27, 2020

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

December 6, 2020

Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

December 6, 2020

Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

December 6, 2020

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

November 8, 2020

Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

November 8, 2020

Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

October 29, 2020

Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

October 4, 2020

Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

September 30, 2020

Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

September 3, 2020

Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health

August 17, 2020

Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

August 10, 2020

Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update

August 9, 2020

Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

August 5, 2020

Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

August 3, 2020

Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 30, 2020

Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

July 28, 2020

Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

July 22, 2020

Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

July 20, 2020

Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

June 30, 2020

Arcturus Therapeutics to be Added to Russell 2000® Index

June 28, 2020

Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

June 10, 2020

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

June 4, 2020

Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

May 7, 2020

Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update

May 6, 2020

Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

May 3, 2020

Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

May 3, 2020

Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate

April 26, 2020

Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock

April 15, 2020

Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

April 12, 2020

Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine

April 8, 2020

Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System

March 26, 2020

Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results

March 10, 2020

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™

March 3, 2020

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11

February 23, 2020

Arcturus Therapeutics to Present at Two Investor Conferences in March

February 18, 2020

Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

January 7, 2020

Calls in 2020

Decks in 2020